Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitoxantrone hydrochloride liposome (CSPC Pharmaceutical Group)
- Development stage
- Unknown
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Duoneda is a liposomal formulation of mitoxantrone hydrochloride, an anthracenedione antineoplastic agent. Developed by CSPC Pharmaceutical Group, it is designed to optimize the therapeutic index of mitoxantrone by utilizing a liposomal delivery system that enhances drug concentration in tumor tissues while minimizing systemic exposure and associated toxicities, such as cardiotoxicity. Mitoxantrone acts by intercalating into DNA and inhibiting topoisomerase II, leading to DNA strand breaks and interference with DNA repair and synthesis. In China, Duoneda was the first liposomal mitoxantrone to receive marketing authorization, specifically for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). It is also being evaluated in clinical trials for other hematological malignancies, including acute myeloid leukemia (AML).
- Brand names
- Duoneda
- Other names
- Mitoxantrone Hydrochloride Liposome InjectionLiposomal mitoxantrone
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on mitoxantrone hydrochloride liposome (CSPC Pharmaceutical Group).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitoxantrone hydrochloride liposome (CSPC Pharmaceutical Group).